<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477139</url>
  </required_header>
  <id_info>
    <org_study_id>BRSADJ0009</org_study_id>
    <secondary_id>97811</secondary_id>
    <secondary_id>BRSADJ0009</secondary_id>
    <nct_id>NCT00477139</nct_id>
  </id_info>
  <brief_title>A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer</brief_title>
  <official_title>A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to gather preliminary data on the baseline immunologic status of&#xD;
      patients with HER-2(+) breast cancer and to establish an immune monitoring laboratory for&#xD;
      future clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study to gather preliminary data on the baseline immunologic status of&#xD;
      patients with HER-2(+) breast cancer and to establish an immune monitoring laboratory for&#xD;
      future clinical trial. We will ask up to 10 patients with HER-2(+) breast cancer in stable&#xD;
      condition and in reasonable health to participate in this study. The study will establish an&#xD;
      immune monitoring for correlative studies done in patients with HER-2(+) breast cancer. The&#xD;
      immunologic tests that will be done are ELISpot, lymphocyte proliferation, intracellular&#xD;
      cytokine staining, lymphocyte immunophenotyping, and ELISA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        individuals with HER-2 positive breast cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years of age&#xD;
&#xD;
          -  Histologically documented breast cancer (hormone receptor (ER/PR) status may be either&#xD;
             positive or negative) with or without metastatic disease.&#xD;
&#xD;
          -  HER-2(+) as determined by one of the following measurements. NOTE: HER-2(+) assessment&#xD;
             may have been on initial diagnosis and need not be repeated for metastatic lesions&#xD;
&#xD;
               -  Immunohistochemistry (IHC) 3+, or&#xD;
&#xD;
               -  FISH + (HER-2 gene signal to centromere 17 signal &gt;2)&#xD;
&#xD;
          -  No transfusion dependent patients and no transfusion within 30 days of leukopheresis&#xD;
&#xD;
          -  Documented labs within 7 days of donation consisting of:&#xD;
&#xD;
               -  WBC &gt; 4.0 K/ul &amp; &lt; 11.0 K/ul&#xD;
&#xD;
               -  platelet count &gt; 150,000/mm3&#xD;
&#xD;
               -  hemoglobin &gt; 11.0 g/dl.&#xD;
&#xD;
               -  Hematocrit &gt; 33 %&#xD;
&#xD;
          -  Weight &gt; 110 lbs&#xD;
&#xD;
          -  No blood donation in last 8 weeks (blood samples taken for standard of care less then&#xD;
             30 cc/week are acceptable)&#xD;
&#xD;
          -  Patients must not have active or unresolved infection.&#xD;
&#xD;
          -  No cold or flu sympton at time of donation&#xD;
&#xD;
          -  No prior myocardial infarction or active cardiac disease (e.g. congestive heart&#xD;
             failure, clinically significant cardiac valvular disease or arrhythmia requiring&#xD;
             medications, angina pectoris, uncontrolled hypertension, clinically significant&#xD;
             pericardial effusion)&#xD;
&#xD;
          -  All patients must give signed written informed consent.&#xD;
&#xD;
          -  ECOG Performance Score of 0 or 1.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of another active malignancy&#xD;
&#xD;
          -  Pregnant, lactating, or nursing&#xD;
&#xD;
          -  Patients with prior myocardial infarction or active cardiac disease (e.g. congestive&#xD;
             heart failure, clinically significant cardiac valvular disease or arrhythmia requiring&#xD;
             medications, angina pectoris, uncontrolled hypertension, clinically significant&#xD;
             pericardial effusion)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Ellie Guardino MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ellie Guardino MD/PhD</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

